About 13 results found for searched term "MEK" (0.06 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1744 | ARRY-162 (Binimetinib) | MEK |
| MEK-162; Binimetinib; ARRY-438162 | ||
| ARRY-162 (MEK-162; Binimetinib) is a selective, potent inhibitor of MEK and cellular pERK with IC50 of 12 nM and 11 nM, respectively. | ||
| M14169 | GDC-0623 | MEK |
| RG 7421; MEK inhibitor 1 | ||
| GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM). | ||
| M14170 | MEK inhibitor | MEK |
| MEK inhibitor is a potent MEK inhibitor with antitumor potency. | ||
| M24647 | Bermekimab | IL Receptor/Related |
| MABp1 | ||
| Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation. | ||
| M24662 | Bimekizumab | IL Receptor/Related |
| Anti-Human IL17A/IL-17F Recombinant Antibody | ||
| Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation. | ||
| M29856 | MEK-IN-4 | MEK |
| MEK-IN-4 is a MEK inhibitor. MEK-IN-4 can be used for the research of inflammatory disorders and cancers. | ||
| M42145 | MEK-IN-6 hydrate | MEK |
| MEK-IN-6 hydrate is a MEK inhibitor. | ||
| M43554 | MEK-IN-6 | ERK |
| MEK-IN-6 is a MEK inhibitor. | ||
| M49714 | MEK1 Derived Peptide Inhibitor 1 | ERK |
| MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. | ||
| M49718 | Myristoyl-MEK1 Derived Peptide Inhibitor 1 | ERK |
| Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1. | ||
| M49720 | STE-MEK1(13) | ERK |
| STE-MEK1(13) (Ste-MPKKKPTPIQLNP-NH?) is a cell permeable ERK1/2 inhibitor (IC50: 13-30?μM). | ||
| M49721 | TAT-MEK1 | ERK |
| TAT-MEK1 is an inhibitor ofERK2, consisting of TAT and MEK1 (N-terminal), TAT (YGRKKRRQRRR) derived from human immunodeficiency (HIV-1) transcriptional trans activator (TAT), is a cell-penetrating peptide. | ||
| M49778 | PROTAC MEK1 Degrader-1 | PROTAC |
| PROTAC MEK1 Degrader-1 is a PROTAC targeting MEK1 with a pIC50 value of 7.0. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
